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Background: Exacerbations are a frequent cause of morbidity and mortality in COPD. It is
crucial to identify risk factors for failure after treatment of exacerbations of COPD. This study
evaluates the COPD severity score (COPDSS) as a predictor of clinical failure, together with
other severity, activity and quality of life measurements, in patients with exacerbated COPD.
Method: Multicenter, prospective, observational study in ambulatory patients with exacerba-
tion of COPD. The patients completed the COPDSS, the London Chest Activities of Daily Living
(LCADL) and the EuroQol 5D (EQ-5D). A follow-up visit was scheduled one month after presen-
tation with the exacerbation to assess the clinical evolution.
Results: A total of 346 patients were included (mean age 68.5 years (SDZ 9.5 years and 90.7%
male) and mean FEV1(% predicted) 46.9% (SDZ 17)). After one month, 28.2% of episodes were
classified as failures, with half of them requiring hospital admission. Patients who failed were
more frequently active smokers, with more severe dyspnoea at presentation and worse lung
function. They had significantly worse scores of COPDSS, LCADL, EQ-5D index and EQ-5D visual
analogue score (VAS) and shorter mean time walking per day. ROC analysis of relationship
between COPDSS and failure gave AUC 0.72, which improved only to 0.77 when the other
significant variables in univariate analysis were considered.
Conclusions: Clinical failure after ambulatory treatment of exacerbation of COPD is frequent.
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COPDSS and exacerbations 741associated with failure; however, a short severity questionnaire (COPDSS) provides better
predictive value than the usual variables.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of disability andmortality andmay affect 7e12% of the
adult population.1 The prevalence of COPD in the adult
population between 40 and 80 years in Spain is 10.2%,2 being
a major problem for the public healthcare system.
The chronic and progressive course of COPD is often
aggravated by exacerbations and these episodes, if frequent,
have demonstrated to have a negative impact on quality
of life in patients with COPD.3e5 Furthermore, exacerbations
are the most frequent cause of medical visits, hospital
admissions and death among patients with chronic lung
disease.6
Most studies consistently showa failure rate of ambulatory
treatment of exacerbations ranging from 15% to 26%.7e11
Since relapse after initial treatment for acute exacerbation
may lead to prolonged disability, an emergency visit or even
hospital admission, it is crucial to identify patients most at
risk for relapse to implement more aggressive treatment and
closer follow-up.
Observational studies have provided information about
risk factors for failure, most being related to baseline
severity of underlying COPD; i.e. impairment in lung func-
tion, advanced age, frequent past exacerbations, previous
hospitalisations.7e13 However,measurements such as health-
related quality of life (HRQoL) questionnaires,14 activity
measurements13 and composite severity scores15,16 have also
provided prognostic value in stable COPD. The aim of the
current study was to evaluate the prognostic value of a new
severity score developed for COPD (COPDSS) to predict clin-
ical failure of ambulatory exacerbations of COPD.
Method
Study design
The ESFERA study (Estudio de Factores predictivos de reso-
lucio´n clı´nica de la EPOC ReAgudizada) was a prospective,
multicentre study carried out with the aim to evaluate the
prognostic value of a new severity score developed for COPD
(COPDSS) to predict clinical failure of ambulatory exacerba-
tions of COPD and compare it with that of other clinical
variables and other frequently used questionnaires such as
the London Chest Activities of Daily Living (LCADL), the
Medical Research Council (MRC) scale of dyspnoea and the
EuroQoL five-dimension questionnaire (EQ-5D). Participating
investigators were respiratory specialists from centres
located throughout Spain. They were requested to include
the first 5 consecutive unselected exacerbated COPD patients
who fulfilled the inclusion and exclusion criteria of the study.
Treatment of exacerbation was left to the criterion of the
investigators. Patients were rescheduled to attend a follow-
up visit one month after the inclusion visit to assess theevolution of the exacerbation. One month was chosen as
a follow-up period because this is the most frequent period
scheduled for a follow-up visit for an ambulatory exacerba-
tion in Spain, and it is well known that exacerbations tend to
cluster in time and the highest risk of relapse occurs during
the first weeks after an episode.17 Questionnaires were
administered in a face-to-face interview during the clinical
visits. No specific training was required for the investigators.
On follow-up visit evolution was classified as success,
including cure (complete resolution of signs and symptoms)
and improvement (a reduction in the symptoms and signs
without new symptoms and signs associated with the exac-
erbation) or failure when there was an absence of resolution
of symptoms and signs, worsening of symptoms and signs or
death.18
Population
Inclusion criteria were ambulatory exacerbated COPD
patients aged 40 years or older, current or ex-smokers with
a smoking history of at least 10 pack-years. The diagnosis of
COPD had to be confirmed by a spirometric test performed
in stable state showing a post-bronchodilator FEV1/
FVC<70%. Exacerbation was defined according to the ERS/
ATS consensus on outcomes for COPD, as an increase in
respiratory symptoms over baseline that usually requires
a change in therapy.19 Exacerbations were classified into
types I, II and III according to the presence of three, two or
only one of the three cardinal symptoms originally described
by Anthonisen et al.20 (increased sputum volume, increased
sputum purulence and worsened dyspnoea).
Participants were excluded if they initially required
admission for treatment of the exacerbation or if they had
been diagnosed with asthma or a chronic respiratory disease
other than COPD, or if patients were diagnosed with
dementia or serious mental illness which would prevent the
understanding of the questionnaires. The study protocol was
approved by the Ethics Committee of the Hospital Clı´nic in
Barcelona (approval number 2007/3793). All patients had to
providewritten informed consent to participate in the study.
Measurements
The sociodemographic characteristics obtainedwere gender,
age and education level. Other variables collected were
COPD-related symptoms, years since diagnosis, body mass
index (BMI), number of exacerbations and hospitalisations
during the previous year, based on self-reporting by the
patient and review of clinical records.
The specific questionnaires used in the study were: a) The
Medical Research Council (MRC) dyspnoea scale.21b) Evalua-
tion of the activities of daily living was measured using the
Spanish version of the LCADL scale.22,23 This tool is focused on
limitations in activity with only 15 items; each item was
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does this for me (or helps)” and the highest LCADL score
reflects greatest disability.24 c) The overall burden of
comorbid diseases was assessed by the Charlson comorbidity
score.25 d) The evaluation of patient HRQoL was performed
by the Spanish version of the self-administered EQ-5D.26,27
The EQ-5D is comprised of a descriptive system and
a visual-analogue scale (VAS) which asks the respondent to
consider and rate his/her health “today”. The VAS score is
anchored at 100 (best imaginable health) and 0 (worst
imaginable health). The data may be used to represent
a profile of health status or converted into a single summary
index (EQ-5D index) by applying scores from an evaluation
set.27 Higher scores of the EQ-5D represent more favourable
health status. Minutes walked per day were recorded based
on patient’s self-reported regular walking times, as in Este-
ban et al.28
Severity of COPD was assessed by the COPD Severity
Score (COPDSS), which includes questions that comprise
five overall aspects of COPD severity: respiratory symp-
toms, systemic corticosteroid use, other COPD medication
use, previous hospitalisation or intubation for respiratory
disease, and home oxygen use. Each item was assigned an
a priori weight based on clinical aspects of the disease and
its expected contribution to overall COPD severity. Missing
values for medication use and other questions were defined
as zero. Possible total scores range from 0 to 35 and higher
scores reflect more severe COPD.29 The questionnaire has
been translated and validated into Spanish.16 All question-
naires were administered by the investigators in a face-to-
face interview.
Statistical analyses
For the sample size calculation, a previous study showed
that a cut off value of 8.5 units in the COPDSS had a sensi-
tivity of 69.7% and a specificity of 71.1% for differentiating
patients with frequent and infrequent exacerbations with
an area under the curve of 0.77. The mean difference in
scores between both groups of patients was 4 units.16 We
aimed to investigate if a difference in score of 4 units in the
COPDSS at onset of exacerbation could identify the patients
most likely to fail after treatment. Assuming a standard
deviation of 7 units, a statistical power of 95%, an alpha risk
of 0.05 and an estimated rate of failure of 15%, a total of
316 patients would be required, plus a 10% loss to follow-up
add up to a sum of 347 individuals.
Mean values and standard deviationswere obtained for all
the variables that followed a normal distribution. Unpaired
Student’s t test was used for comparison of independent
data that followed a normal distribution. Non normally
distributed variables were compared by means of the Wil-
coxon test. The Student’s t test for repeated measurements
was used for paired data, if they followed a normal distri-
bution. Otherwise, the Wilcoxon rank sum test was applied.
The chi-square (c2) test was used for the comparison of
categorical variables, as in the comparison of the distribu-
tion of the rates of failure among the different tertiles of the
variables of interest.
The area under the receiver operating characteristic (AU
ROC) curves was calculated to evaluate the discrimination
between failure and success for each variable.30 Theanalysis was performed using SAS software (SAS Institute,
Cary, SC, USA) version 9.1 for Windows. All tests were two-
tailed and the level of significance was set at 0.05.Results
A total of 91 pulmonologists accepted to participate in
the study and collected information from 425 patients.
However, 79 (18.6%) patients were excluded from the study,
mostly due to non compliance with spirometric criteria for
COPD (n Z 50), not fulfilling other inclusion or exclusion
criteria (nZ 13) or lack of follow-up at one month (nZ 16).
The characteristics of the 346 patients included in the
study are described in Table 1. Most of the subjects were
male (90.7%) and during the last 12 months the patients
reported a mean of 2 exacerbations (SD Z 1.9) due to
COPD. Mean post-bronchodilator FEV1 (% predicted) was
46.9% (SD Z 17%). Only 8 patients (3%) were in GOLD
stage I, 36.5% in Stage II, 44.4% in stage III and 16% in stage
IV. Treatments administered for COPD were: long-acting
beta-2 agonists 89.6%, anticholinergics 84%, inhaled corti-
costeroids 83.2%, short-acting beta-2 agonists 70.7% and
teophyllines 22.5% and oral corticosteroid use for more
than 3 months in the last 2 years 14%.
Scores obtained in the questionnaires are showed in
Table 2. Most exacerbations were type I (73.4%) and the
treatment prescribed consisted of antibiotics in 93.3%,
a short course of oral corticosteroids in 63.1% and increased
doses of bronchodilators in 75.5% of cases.
At the one month follow-up, a total of 249 (71.8%)
episodes were classified as success and 97 (28.2%) as
failure. Of these, 49 (50.5% of failures and 14.1% of the
total population) required hospital admission, 22 (22.7% of
failures and 6.3% of the total) were attended in emergency
rooms and the remaining 26 patients (26.8% of failures and
7.5% of total) required changes in treatment and/or did not
return to baseline after follow-up.
At the end of follow-up, patients experienced a change
in scores of the EQ-5D index of a mean of 0.07 units and of
7.62 units for the VAS. The COPDSS improved a mean of
almost one unit (0.95 units; SD Z 2.7 units) and physical
activity also improved, measured both as minutes walked
per day and the scores of the LCADL (Table 2).
Patients who failed were more frequently active
smokers (27.8% versus 16.1%; p Z 0.014), had a more
severe dyspnoea degree at presentation (3.4 (0.9) versus
2.9 (SD Z 0.9); p < 0.001) and had more frequent exac-
erbations and admissions the previous year. The remaining
clinical and demographic characteristics were not different
between groups (Table 1).
Table 3 shows differences in scores of the questionnaires
and physical activity at onset of the exacerbation between
patients who failed and those who improved after treat-
ment. There were significant differences at presentation in
the EQ-5D index and VAS, COPDSS, LCADL and minutes
walked per day between patients who subsequently would
experience a treatment failure and those who were treated
successfully (p values between 0.034 for LCADL to <0.001
for COPDSS). Interestingly, the magnitude of the changes in
scores from onset of exacerbation to one-month follow-up
between patients with different clinical evolution were not
Table 1 Demographic and clinical characteristics of COPD patients participating in the study and comparison of baseline
values between patients grouped according to the evolution of the exacerbation.
Variable All N Z 346 Clinical
success N Z 249
Clinical
failure N Z 97
P value
Age (years) 68.5 (9.5) 68.3 (9.6) 69.1 (9.5) 0.35
BMI (Kg/m2) 27.4 (4.7) 27.6 (4.5) 26.9 (5) 0.33
Sex, Male (%) 90.7 91 89.6 0.68
Current smoker (%) 19.3 16.1 27.8 0.014
Pack-years 50.9 (29.5) 49.4 (29.5) 53.4 (29.4) 0.21
Years since COPD diagnosis 9.4 (6.8) 9.3 (6.7) 9.8 (7) 0.58
COPD exacerbations last year 2 (1.9) 1.7 (1.3) 2.6 (2.7) 0.005
Hospitalisations due to
COPD last year
0.45 (1.01) 0.6 (1.2) 2.1 (2.3) <0.001
MRC dyspnoea degree 3.0 (0.8) 2.9 (0.9) 3.4 (0.9) <0.001
Charlson comorbidity index 2.03 (1.3) 1.98 (1.2) 2.2 (1.4) 0.25
Post-bronchodilator
spirometry
FVC, ml 2,615 (812) 2,668 (844) 2,459 (701) 0.08
FVC, % 63.7 (18.2) 64.6 (18.2) 60.8 (18) 0.12
FEV1, ml 1,363 (542) 1,398 (562) 1,255 (467) 0.07
FEV1 (%) 46.9 (17) 47.8 (17.1) 43.9 (16.2) 0.09
FEV1/FVC 52.5 (11.1) 52.7 (11.1) 51.8 (10.9) 0.52
Exacerbation type
Type I 73.4 71.6 77.3 0.11
Type II 18.8 21.4 12.4
Type III 7.8 6.9 10.3
Treatment with antibiotics (%) 93.3 90.7 97.9 0.009
Treatment with OC 63.1 54.8 80.4 <0.001
*Data are presented as mean  SD or No. (%).
Clinical success includes cure (complete resolution of signs and symptoms) and improvement (a reduction in the symptoms and signs
without new symptoms and signs associated with the exacerbation). Failure was defined as an absence of resolution of symptoms and
signs, worsening of symptoms and signs or death. OCZ oral corticosteroids; FEV1Z forced expiratory volume in 1 s; FVCZ forced vital
capacity; FEV1% Z percentage of predicted FEV1; FVC% Z percentage of predicted FVC.
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(Table 3). Only time walked per day increased by almost
15 min in patients who were successfully treated compared
with an irrelevant increase of 3 min in those who failed
(p Z 0.019).Table 2 Outcome measurements in the study population at exa
Outcome
measurement
tools
Baseline
(exacerbation)
HRQoL and
severity
EQ-5D index 0.54 (0.23)
EQ VAS 34.4 (27.4)
Total COPDSS 14.2 (5.5)
Activity
Mean time walking
per day (minutes)
61.2 (47.9)
Total LCADL 27.2 (12.9)
Self-care domain 8.3 (4.1)
Domestic domain 7 (8.8)
Physical domain 5.5 (1.8)
Leisure domain 5.1 (2.4)
Values are mean (standard deviation).Rates of failure were only significantly different according
to the different distribution in tertiles of minutes walked per
day (pZ 0.001), EQ-5D VAS (pZ 0.003) and score of COPDSS
(p< 0.0001). For the latter questionnaire, the rate of failure
of the patients in the first tertile (2e11 units) was 12.2%,cerbation and after one month for the whole population.
1-month
follow-up
Mean
change (SD)
0.61 (0.21) 0.07 (0.17)
41.8 (31.2) 7.62 (13.8)
13.2 (5.4) 0.95 (2.7)
71.5 (55.9) 11.6 (38.8)
24.4 (12.5) 2.7 (6.3)
7.4 (3.9) 0.9 (2)
6.4 (8.5) 0.6 (5.2)
4.7 (1.9) 0.8 (0.7)
4.4 (2) 0.7 (0.8)
Table 3 Evolution of outcome measurements from onset
of exacerbation (baseline) to one-month follow-up and
comparison of baseline values between patients grouped
according to the evolution of the exacerbation.
Variable Clinical
success
N Z 249
Clinical
failure
N Z 97
P value
HRQoL and severity
EQ-5D index
Baseline 0.57 (0.22) 0.48 (0.25) 0.002
1-month follow-up 0.65 (0.18) 0.53 (0.24)
Change 0.08 (0.15) 0.05 (0.21) 0.25
EQ VAS
Baseline 37.1 (28.1) 27.8 (24.3) 0.003
1-month follow-up 44.5 (31.5) 35.4 (29.8)
Change 7.7 (13.5) 7.5 (14.7) 0.67
Total COPDSS
Baseline 12.9 (5) 17.1 (5.4) <0.001
1-month follow-up 11.9 (4.9) 16.1 (5.4)
Change 1.06(2.3) 0.71 (3.5) 0.19
Activity
Mean time walking
per day (minutes)
Baseline 66.5 (45.2) 47.7 (52.2) <0.001
1-month follow-up 79.8 (56.3) 51.4 (50)
Change 14.8 (41.2) 3.6 (31.3) 0.019
Total LCADL
Baseline 26.2 (12.3) 29.9 (14.2) 0.034
1-month follow-up 23.3 (11.1) 27.4 (15.2)
Change 2.87(5.4) 2.12 (8.2) 0.99
The first p value for each variable corresponds to the compar-
ison between baselines values of patients who were successfully
treated and those who relapsed, at the time of presentation
with the exacerbation. The second p value corresponds to the
comparison of the changes in scores for each variable between
the same groups of patients (Student’s t test or Wilkoxon rank
sum test). Values are means (standard deviations).
744 M. Miravitlles et al.whereas that of patients in the third tertile (20e30 units) was
up to 53.4% (Fig. 1).
The receiver operating characteristic (ROC) curve showed
that the COPDSS score had good discriminative capability for
failure with an AUC of 0.72 (Fig. 2). This AUC was higher than
that obtained for the LCADL(0.59), EQ-5D index (0.62) and
EQ-5D VAS (0.60) (Fig. 2). For comparison, when considering
all the variables that were significant in the univariate anal-
ysis, the discriminative power only increased to an AU ROC
curve of 0.77.
Discussion
Our results in a large unselected population of patients with
exacerbated COPD show that a simple severity scale, the
COPDSS, is a significant predictor of clinical failure and
showed the best discrimination among all variables used
in the analysis. Moreover, when considering all variables
that showed a significant association with failure in the
univariate analysis, there was no significant increase indiscrimination compared with the use of the COPSS alone
for the prediction of clinical failure.
The reason for this lack of increased discrimination with
other variables comes from the design of the COPDSS. This
short questionnaire provides accurate information about
the severity of COPD and includes questions about symp-
toms, previous exacerbations and treatment. Therefore,
similar information collected in other questionnaires was
already included in the COPDSS. In addition, in our previous
study, the COPDSS correlated with the EQ-5D index
(r Z 0.553; p < 0.001) and VAS (r Z 0.505; p < 0.001)
and with the score of the LCADL questionnaire (r Z 0.465,
p < 0.001).16 The best discrimination of the COPDSS
compared with these questionnaires probably derives from
the fact that the COPDSS collects specific information
regarding COPD, whereas the other questionnaires are
generic instruments, not specific for respiratory diseases.
The COPDSS was developed and validated by Eisner and
coworkers6 and its validity was demonstrated in a population
of 383 US adults with self-reported physician-diagnosed
COPD. The Spanish version of the questionnaire was vali-
dated by our group in a population of 827 patients with
spirometry-diagnosed COPD.16 In a recent study Eisner
et al.31 prospectively demonstrated that higher COPDSS
were associated with a greater risk of acute exacerbation of
COPD requiring emergency visit, hospitalisation or either
indicator of hospital-based care for COPD. In the current
study, we have extended these observations by demon-
strating that the COPDSS evaluated at onset of exacerbation
was significantly related to the clinical success of treatment
and was the best independent predictor of outcome. In fact,
those who scored below 12 units only had a 12.2% rate of
failure compared with 53.4% of failures in those with a score
of 20 or higher. A new finding of our study is that the COPDSS
was not useful to monitor the evolution of the exacerbation,
because the scores of both, patients who failed and those
whowere cured, did not significantly change at onemonth of
follow-up. These results mean that the COPDSS is not
sensitive to detect acute changes in health status or in the
severity of the disease. Similarly, the other scales used in
this study did not provide a good measurement of change
from the onset of exacerbation to one month after the
episode. Other recently developed questionnaires, such as
the COPD Assessment Test (CAT) may be more useful to
monitor the evolution of exacerbations, but its predictive
value for failure of exacerbations has not yet been
adequately assessed.32
Interestingly, the second best predictor of outcome was
the self declared time walked per day, with patients who
walked less than 30 min per day having 40.7% of failures
compared with those who walked more than 1 h with 11.7%
of failures. Similarly, a low level of self-reported regular
physical activity was identified as a risk factor for admis-
sions and mortality in a population-based sample of COPD
patients,33 and patients with a recent hospitalisation for an
exacerbation had a lower activity level compared with
those not hospitalised and reduced activity persisted for
more than one month after admission.34 Our observations
concur with the previously mentioned study because there
was an increase in time walked per day of only 11 min at
one month after the onset of exacerbation (15 min for those
who were successfully treated). These results confirm the
Figure 1 Percentage of patients who failed after treatment of an exacerbation of COPD according to the tertile distribution of
the following: a: FEV1 (% predicted) and minutes walked per day. b: Scores of EQ-5D index and EQ-5D VAS. c: Scores of COPDSS and
LCADL.
COPDSS and exacerbations 745close relationship between physical activity level, health,
disability and exacerbations.35,36
The failure rate of 28.2% observed in our study is high but
similar to that obtained in other observational studies,
ranging from 18% to 25%.7e11 Therefore, it is crucial to
identify the patients most at risk of failure to intensify
therapy and organise a closer follow-up. This has been rec-
ognised in recent guidelines that stratify patients according
to the risk factors of failure.37e39 The inclusion of easy
questionnaires such as the COPDSS could help to better
stratify patients into risk categories and alert attending
physicians about those at high risk of failure.
The risk factors identified on univariate analysis were
those traditionally described 713: frequent exacerbationsthe previous year, active smoking and hospitalisation the
previous year, with lung function having borderline signifi-
cance. Patients treated with systemic corticosteroids had
a significantly increased risk of failure, being a clear case of
bias by indication, because only the most severe exacerba-
tions were treated with a short course of these drugs. The
interest of our findings is that the COPDSS alone was a better
predictor of failure than the combination of the other known
risk factors. This is of great interest because the COPDSS can
be completed in the clinical visit in no more than 5 min.
Our study has several limitations, 90.7% of our population
were males, which is in agreement with the epidemiological
characteristics of COPD in Spain,2 but the extrapolation of
these results to women should be made with caution.
Figure 2 ROC curve analysis of different questionnaires and
failure. COPDSS: COPD Severity Score, AUC Z 0.72; LCADL:
London Chest Activities of Daily Living, AUC Z 0.59; EuroQOL:
EuroQoL five-dimension questionnaire, AUC Z 0.62; EuroQOL
Thermometer: EuroQoL visual-analogue scale, AUC Z 0.60.
746 M. Miravitlles et al.Furthermore, the validation of the COPSS in Spain did not
consider this difference in the proportion of women
compared with the sex distribution of COPD patients in the
US where the questionnaire was originally developed.16,29
However, the current results can be compared with the
previous Spanish study, because the sex distribution of the
patients included is similar.16 The one month follow-up
prevents any conclusion to be drawn about the prognostic
value of the COPDSS on long-termoutcomes, such as the time
to the next exacerbation or mortality. Long-term studies
should be designed to adequately address these aspects.
In summary, there is a high rate of clinical failure after
ambulatory treatment of exacerbations of COPD. The
COPDSS is a very useful tool for stratifying the risk of failure
and can be completed in less than 5 min during the clinical
visit. Simple and reliable severity scales should be imple-
mented in management guidelines.
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